The chief executive of Novavax, Stanley told the Czech daily ‘ Hospodarske Noviny’ that the firm has plans of producing a part of the vaccine NVX-CoV2373, at its Czech plant. With this, the European Nation will have access to the vaccine once it gets approval. For approval, the company has planned to file for one in the US in December.
For its ongoing clinical trial of phase II of the vaccine, the company has already started to enroll volunteers. The phase II trial expands on age group which will include older communities, who age between 60-84 years of age. The company is also expecting interim data from the trial in the fourth quarter.
Novavax said the clinical trial in the II phase is the mostly placebo-controlled and randomized study which shall evaluate the efficiency and safety of the vaccine candidate. The company will enroll around 1500 healthy volunteers, out of which 50 % of participants shall be above 60 years of age.